Predict your next investment

HEALTHCARE | Drug Discovery

See what CB Insights has to offer

Founded Year




Total Raised


Date of IPO




About Exscientia

Exscientia (NASDAQ: EXAI) is an AI-driven, drug discovery, and design enterprise. Exscientia aims to use AI to discover and design better quality drugs with greater efficiency.

Exscientia Headquarter Location

The Schrodinger Building Oxford Science Park

Oxford, England, OX4 4GE,

United Kingdom

+44 (0) 1865 818941

Latest Exscientia News

Exscientia to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

Nov 23, 2021

November 23, 2021 08:00 AM Eastern Standard Time OXFORD, England--( BUSINESS WIRE )--Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO, Ben Taylor, CFO & Chief Strategy Officer, and Garry Pairaudeau, Chief Technology Officer, will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 10:30 a.m. ET (3:30 p.m. GMT). A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at . An archived replay of the webcast will be available for approximately 30 days following the presentation. About Exscientia Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline of internal and partnered programmes demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials. Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston, and Osaka. For more information visit us on or follow us on Twitter @exscientiaAI . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Exscientia

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Exscientia is included in 3 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

7,904 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.



14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Digital Health

11,292 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Exscientia Patents

Exscientia has filed 1 patent.

The 3 most popular patent topics include:

  • Acetylcholinesterase inhibitors
  • Adenosine receptor antagonists
  • Carbamates
patents chart

Application Date

Grant Date


Related Topics



Adenosine receptor antagonists, Carbamates, Xanthines, Acetylcholinesterase inhibitors, Purines


Application Date


Grant Date


Related Topics

Adenosine receptor antagonists, Carbamates, Xanthines, Acetylcholinesterase inhibitors, Purines



Exscientia Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Exscientia Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.